Conversión de prueba cutánea de derivado proteico purificado durante el tratamiento con anti-TNF-α

  • Brian Marcelo Abdala Hospital Provincial del Centenario, Rosario, Santa Fe, Argentina
  • Ariana Ringer Hospital Provincial del Centenario, Rosario, Santa Fe, Argentina
  • Juan Pablo Ruffino Hospital Provincial del Centenario, Rosario, Santa Fe, Argentina
  • María Florencia Martínez Hospital Provincial del Centenario, Rosario, Santa Fe, Argentina
  • María Cecilia Argento Hospital Provincial del Centenario, Rosario, Santa Fe, Argentina
  • Serenela Chulibert Hospital Provincial del Centenario, Rosario, Santa Fe, Argentina
  • Daniela Carbone Hospital Provincial del Centenario, Rosario, Santa Fe, Argentina
  • Franco Lucci Hospital Provincial del Centenario, Rosario, Santa Fe, Argentina
  • Agostina Gatica Hospital Provincial del Centenario, Rosario, Santa Fe, Argentina
  • Graciela Rombo Hospital Provincial del Centenario, Rosario, Santa Fe, Argentina
  • Mariano Palatnik Hospital Provincial del Centenario, Rosario, Santa Fe, Argentina
  • María Noel Cortese Hospital Provincial del Centenario, Rosario, Santa Fe, Argentina
  • Mariana Lagrutta Hospital Provincial del Centenario, Rosario, Santa Fe, Argentina
  • Baltasar Finucci Curi Hospital Provincial de Rosario, Rosario, Santa Fe, Argentina
  • Adriana Co Hospital Provincial de Rosario, Rosario, Santa Fe, Argentina
  • Marcelo Alberto Abdala Hospital Provincial del Centenario, Rosario, Santa Fe, Argentina
Palabras clave: enfermedades reumáticas, anti-TNF-α, conversión PPD, infección de tuberculosis latente, infección tuberculosa

Resumen

Introducción: los anti-TNF-α se asocian con mayor riesgo de desarrollar tuberculosis (TB). La prueba del derivado proteico purificado (purified protein derivative, PPD) se emplea para diagnosticar infección de tuberculosis latente (ITL). Se recomienda el cribado para TB previo al inicio de terapia anti-TNF-α y el seguimiento para evaluar la posible conversión de la PPD durante el tratamiento. El tratamiento de la ITL puede reducir el riesgo de desarrollar enfermedad activa en un 90%. Objetivos: actualmente los resultados de conversión de la PPD y su interpretación durante el tratamiento anti-TNF-α son variables, por tal motivo nos propusimos conocer la frecuencia de conversión de la PPD en este grupo de pacientes de nuestro medio.

Biografía del autor/a

Brian Marcelo Abdala, Hospital Provincial del Centenario, Rosario, Santa Fe, Argentina
Servicio de Reumatología
Ariana Ringer, Hospital Provincial del Centenario, Rosario, Santa Fe, Argentina
Servicio de Reumatología
Juan Pablo Ruffino, Hospital Provincial del Centenario, Rosario, Santa Fe, Argentina
Servicio de Reumatología
María Florencia Martínez, Hospital Provincial del Centenario, Rosario, Santa Fe, Argentina
Servicio de Reumatología
María Cecilia Argento, Hospital Provincial del Centenario, Rosario, Santa Fe, Argentina
Servicio de Reumatología
Serenela Chulibert, Hospital Provincial del Centenario, Rosario, Santa Fe, Argentina
Servicio de Reumatología
Daniela Carbone, Hospital Provincial del Centenario, Rosario, Santa Fe, Argentina
Servicio de Reumatología
Franco Lucci, Hospital Provincial del Centenario, Rosario, Santa Fe, Argentina
Servicio de Reumatología
Agostina Gatica, Hospital Provincial del Centenario, Rosario, Santa Fe, Argentina
Servicio de Reumatología
Graciela Rombo, Hospital Provincial del Centenario, Rosario, Santa Fe, Argentina
Servicio de Reumatología
Mariano Palatnik, Hospital Provincial del Centenario, Rosario, Santa Fe, Argentina
Servicio de Reumatología  
María Noel Cortese, Hospital Provincial del Centenario, Rosario, Santa Fe, Argentina
Servicio de Reumatología
Mariana Lagrutta, Hospital Provincial del Centenario, Rosario, Santa Fe, Argentina
Servicio de Clínica Médica
Baltasar Finucci Curi, Hospital Provincial de Rosario, Rosario, Santa Fe, Argentina
Servicio de Clínica Médica
Adriana Co, Hospital Provincial de Rosario, Rosario, Santa Fe, Argentina
Servicio de Clínica Médica
Marcelo Alberto Abdala, Hospital Provincial del Centenario, Rosario, Santa Fe, Argentina
Servicio de Reumatología

Citas

I. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An endotoxininduced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A 1975; 9(72);3666-3670.

II. Koo S, Marty FM, Baden LR. Infectious complications associated with immunomodulating biologic agents. Infect Dis Clin North Am 2010; 24(2):285-306.

III. García-Doval I, Hernández MV, Vanaclocha F, Sellas A, de la Cueva P, Montero D; BIOBADADERM and BIOBADASER study groups. Should tumour necrosis factor antagonist safety information be applied from patients with rheumatoid arthritis to psoriasis? Rates of serious adverse events in the prospective rheumatoid arthritis BIOBADASER and psoriasis BIOBADADERM cohorts. Br J Dermatol 2017 Mar;176(3):643-649.

IV. Rosa J, Sabelli M, Soriano ER. Prefilled certolizumab pegol (Cimzia®) syringes for self-use in the treatment of rheumatoid arthritis. Med Devices (Auckl) 2010;3:25-31.

V. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alphaneutralizing agent. N Engl J Med 2001; 345(15):1098-104.

VI. Brassard P, Kezouh A, Suissa S. Antirheumatic drugs and the risk of tuberculosis. Clin Infect Dis 2006;43(6):717-22.

VII. Tubach F, Salmon D, Ravaud P, et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum 2009;60(7):1884-94.

VIII. Dixon WG, Hyrich KL, Watson KD, et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BS-RBR). Ann Rheum Dis 2010;69(3):522-8.

IX. Jordán R, Valledor A. Guías de recomendaciones de prevención de infecciones en pacientes que reciben modificadores de la respuesta biológica. Rev Arg Reumatol 2014;25(2): 08-26

X. Winthrop KL, Novosad SA, Baddley JW, et al. Opportunistic infections and biologic therapies in immunemediated inflammatory diseases: consensus recommendations for infection reporting during clinical trials and postmarketing surveillance. Ann Rheum Dis 2015;74(12):2107-16.

XI. Lewinsohn DM, Leonard MK, LoBue PA, et al. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of tuberculosis in adults and children. Clin Infect Dis 2017;64(2):e1-e33.

XII. Bossio JS, Fernández H, Arias S, et al. La tuberculosis en números. Boletín sobre tuberculosis en Argentina 2019;2(2):12-22.

XIII. Pai M, Behr MA, Dowdy D, et al. Tuberculosis. Nat Rev Dis Primers 2016; 2:16076.

XIV. Comstock GW. How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults? Int J Tuberc Lung Dis 1999 Oct;3(10):847-50.

XV. Mazurek GH, Jereb J, Vernon A, LoBue P, Goldberg S, Castro K; IGRA Expert Committee; Centers for Disease Control and Prevention (CDC). Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection. United States, 2010. MMWR Recomm Rep 2010:25;59(5):1-25.

XVI. WHO. Latent tuberculosis infection: updated and consolidated guidelines for programmatic management. Geneva: World Health Organization; 2018.

XVII. Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement. Am J Respir Crit Care Med 2000; 161(4 Pt 2):S221-47.

XVIII. Menzies D, Doherty TM. Diagnosis of latent tuberculosis infection. In: Reichman and Hershfield’s Tuberculosis, a comprehensive international approach, Raviglione MC (Ed), Informa Healthcare USA, New York 2006.; p.215.

XIX. Duboczy Bo, Brown Bt. Multiple readings and determination of maximal intensity of tuberculin reaction. Am Rev Respir Dis 1961;84:60-8.

XX. Abbate E, Ballester D, Barrera L, Brian MC, Echazarreta A, Gaitan C, et al. Consenso Argentino de Tuberculosis. Rev Arg Med Resp 2009;9:61-9.

XXI. D’Orazio A, Lencina MV. Agentes biológicos anti-factor de necrosis tumoral alfa. Actualización de las guías de práctica clínica en el tratamiento de la artritis reumatoidea. Revista Argentina de Reumatología 2013;206-207.

XXII. Joven BE, Almodovar R, Galindo M, Mateo I, Pablos JL. Does anti-tumour necrosis factor a treatment modify the tuberculin PPD response? Ann Rheum Dis 2006;65:699.

XXIII. Cascante J, Pascal I, Eguía VM, Hueto J. Diagnóstico de la infección tuberculosa. Anales Sis San Navarra 2007;30(2): 49-65.

XXIV. Mancuso JD, Mody RM, Olsen CH, et al. The Long-term effect of Bacille Calmette-Guérin vaccination on tuberculin skin testing: A 55-year follow-up Study. Chest 2017;152(2):282-294.

XXV. Menzies D. Interpretation of repeated tuberculin tests. American Journal of Respiratory and Critical Care Medicine 1999;159(1):15-21.

XXVI. Esmail H, Wilkinson R. Minimizing tuberculosis risk in patients receiving anti-TNF therapy. Annals of the American Thoracic Society 2017;14(5):621-623.

XXVII. Fuchs I, Avnon L, Freud T, Abu-Shakra M. Repeated tuberculin skin testing following therapy with TNF-alpha inhibitors. Clinical Rheumatology 2008;28(2):167-172.

XXVIII. Cerda O, Correa M, Granel A, Marcos A, Giraldo C, Rillo O, et al. Tuberculin test conversion in patients with chronic inflammatory arthritis receiving biological therapy. European Journal of Rheumatology 2019;6(1):19-22.

XXIX. Busquets-Pérez N, Ponce A, Ortiz-Santamaria V, de Agustín de Oro J, Hernández-Rico Y, Vidal I, et al. How many patients with rheumatic diseases and TNF inhibitors treatment have latent tuberculosis? Reumatol Clin 2020;13(5):282-286.

XXX. Cano-Portero R, Amillateguidos Santos R, Boix-Martínez R, Larrauri-Cámara A. Epidemiología de la tuberculosis en España. Resultados obtenidos por la Red Nacional de Vigilancia Epidemiológica en el año 2015. Enfermedades Infecciosas y Microbiología Clínica. 2018;36(3):179-186.

XXXI. Taxonera C, Ponferrada Á, Riestra S, Bermejo F, Saro C, Martín-Arranz M, et al. Serial tuberculin skin tests improve the detection of latent tuberculosis infection in patients with inflammatory bowel dsease. Journal of Crohn’s and Colitis. 2018; 12(11):1270-1279.

XXXII. Trinh H, Tabechian D. Incidence of conversion of screening tests for M. Tuberculosis (PPD, GIF‐release assay) in a metropolitan cohort of patients treated with TNF‐α inhibitors. Arthritis Rheumatol 2018;70:10.

XXXIII. Hatzara C, Hadziyannis E, Kandili A, Koutsianas C, Makris A, Georgiopoulos G, et al. Frequent conversion of tuberculosis screening tests during anti-tumour necrosis factor therapy in patients with rheumatic diseases. Annals of the Rheumatic Diseases 2014;74(10):1848-1853

XXXIV. Park J, Seo G, Lee J, Kim T, Yoo D. Positive conversion of tuberculin skin test and performance of interferon release assay to detect hidden tuberculosis infection during anti-tumor necrosis factor agent trial. The Journal of Rheumatology 2009; 36(10):2158-2163.

Publicado
2021-12-01
Cómo citar
1.
Abdala BM, Ringer A, Ruffino JP, Martínez MF, Argento MC, Chulibert S, Carbone D, Lucci F, Gatica A, Rombo G, Palatnik M, Cortese MN, Lagrutta M, Finucci Curi B, Co A, Abdala MA. Conversión de prueba cutánea de derivado proteico purificado durante el tratamiento con anti-TNF-α. Rev. Argent. Reumatol. [Internet]. 1 de diciembre de 2021 [citado 16 de mayo de 2022];32(4):26 -32. Disponible en: https://ojs.reumatologia.org.ar/index.php/revistaSAR/article/view/509
Sección
Artículo Original